Expanded Hemodialysis Therapy Market - Growth Drivers and Challenges
Growth Drivers
- Growing Cases of End-Stage Kidney Disease (ESKD) – The prevalence of end-stage kidney disease (ESKD) is growing on the account of the rapid escalation of unhealthy lifestyles and the adoption of destructive food items which are packaged and processed. This trend is anticipated to decrease the functioning capacity of the kidney which generates the need for expanded hemodialysis therapy for the treatment process. Hence, the rising cases of end-stage kidney disease (ESKD) among the global population are anticipated to bring positive opportunities for market growth during the forecast period. The National Institute of Diabetes and Digestive and Kidney Diseases stated that nearly 786,000 people in the United States were living with end-stage kidney disease in 2020, out of which almost 71% were on dialysis and 29% with a kidney transplant.
- Increased in Lifestyle Disorders – In the recent period, the rate of lifestyle disorders such as diabetes and hypertension has grown considerably owing to poor diet, sedentary lifestyle, reduced physical activity, high consumption of alcohol, and others. People diagnosed with such diseases are considered to be more prone to develop a kidney disorder. Thus, failure of kidneys owing to lifestyle diseases is estimated to increase the utilization rate of expanded hemodialysis therapy and subsequently expand the market size. As per the data shared by the World Health Organization (WHO), it has been estimated that diabetes was responsible for 1.5 million deaths which are equivalent to 48% of all death across the globe in 2019. On the other hand, WHO also stated that the number of people living with hypertension across the globe has doubled to 1.28 in the last thirty years.
- Burgeoning Geriatric Population in the World – Elderly people have a higher risk of kidney failure owing to a greater chance of being affected by diseases and weakened immunity along with deteriorating body organs. This results in proper dialysis for enhancing the survival rates which is projected to impetus the use of expanded hemodialysis therapy in the upcoming years. As per the estimations, the number of old people across the world is expected to double by 2050 and reach 2 billion up from 1.5 billion in 2030.
- Constant Support from the Government to Treat Chronic Kidney Disease – The government of different nations are focusing on building better healthcare facilities and providing enhanced healthcare policies for various diseases, including chronic kidney disease. This factor is attributed to bringing in lucrative growth opportunities for market growth during the assessment period. For instance, the Centers for Medicare & Medicaid Services (CMS) declared the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model to provide quality care by reducing chronic kidney disease expenditure for patients. This ETC model is estimated to boost the economy by saving around USD 23 million in five and a half years.
Challenges
- Complications and Risks Associated with Dialysis – In some cases, patients treated with expanded hemodialysis therapy face acute complications during the procedure. One of the most common complications that arise is anemia i.e. insufficient red blood cells in the body. Also, people after expanded hemodialysis therapy may experience swelling, redness, warmth, and pain in the whole body. These factors couple up to pose a challenge to market growth during the forecast period.
- High Costs of the Expanded Hemodialysis Therapy Procedure
- Lack of Awareness about Kidney Diseases and their Treatment
Expanded Hemodialysis Therapy Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
4.9% |
|
Base Year Market Size (2025) |
USD 95.07 billion |
|
Forecast Year Market Size (2035) |
USD 153.39 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of expanded hemodialysis therapy is evaluated at USD 99.26 billion.
The global expanded hemodialysis therapy market size exceeded USD 95.07 billion in 2025 and is set to expand at a CAGR of over 4.9%, surpassing USD 153.39 billion revenue by 2035.
North America is anticipated to command a 35% share by 2035 in the expanded hemodialysis therapy market, supported by escalating healthcare expenditure, higher disposable incomes, and growing demand for advanced product development.
Key players in the market include B. Braun Melsungen AG, Asahi Kasei Corporation, Baxter International, Inc., Fresenius Medical Care AG & Co. KGaA, Nikkiso Co., Ltd., Nipro Corporation, NxStage Medical, Inc., Cantel Medical Corp., Satellite Healthcare, Inc., MEDIVATORS, Inc.